JARDIANCE® under the microscope: can it safely protect kidneys Long-Term?
NCT ID NCT06527846
First seen Jan 04, 2026
Summary
This study is tracking over 1,000 Japanese patients with chronic kidney disease who are taking JARDIANCE® (empagliflozin) daily for a long period. Researchers are monitoring side effects and whether the drug helps slow kidney decline in real-world conditions. The goal is to see if the medication remains safe and effective outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (JARDIANCE®)
What this could lead to
If successful, this study could confirm that JARDIANCE® is safe and effective for long-term use in slowing kidney disease progression in a real-world setting.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It only includes Japanese patients, so findings may not apply to other populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.